Cantor Fitzgerald Estimates Septerna FY2024 Earnings

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Septerna in a report issued on Tuesday, November 19th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn ($5.19) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $50.00 price objective on the stock.

Several other research analysts have also issued reports on the company. Wells Fargo & Company assumed coverage on Septerna in a report on Tuesday. They issued an "overweight" rating and a $43.00 price target on the stock. TD Cowen assumed coverage on Septerna in a report on Tuesday. They issued a "buy" rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Septerna in a report on Tuesday. They issued an "overweight" rating and a $38.00 price target on the stock.

Septerna Stock Performance

Shares of Septerna stock traded up $0.21 on Friday, hitting $22.00. 96,279 shares of the company's stock traded hands, compared to its average volume of 193,884. Septerna has a one year low of $18.62 and a one year high of $26.34.

Insiders Place Their Bets

In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the business's stock in a transaction dated Monday, October 28th. The stock was purchased at an average cost of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the acquisition, the insider now directly owns 6,215,591 shares of the company's stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.